Literature DB >> 15236178

A novel triterpenoid induces transforming growth factor beta production by intraepithelial lymphocytes to prevent ileitis.

Laurie A Minns1, Dominique Buzoni-Gatel, Kenneth H Ely, Nicolas Rachinel, Souphalone Luangsay, Lloyd H Kasper.   

Abstract

BACKGROUND & AIMS: The loss of homeostasis is a hallmark of inflammatory bowel disease. Oral infection of susceptible mice with Toxoplasma gondii results in an acute lethal ileitis characterized by increased interferon gamma, tumor necrosis factor alpha, and inducible nitric oxide synthase; homeostasis results from transforming growth factor beta production by intraepithelial lymphocytes. The synthetic oleanane triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) is a potent anti-inflammatory molecule previously shown in vitro to suppress the de novo synthesis of inducible nitric oxide synthase and to induce the transcription and activation of genes from the transforming growth factor beta signaling pathway.
METHODS: We evaluated the immune response in the small intestine and by intraepithelial lymphocytes after a single intraperitoneal dose of CDDO at the time of T. gondii oral infection. We abrogated the homeostatic effects of CDDO by blocking transforming growth factor beta in vivo.
RESULTS: CDDO acid prevented ileitis development through the global down-regulation of inflammatory cytokines and chemokines. Total transforming growth factor beta(1) production by the intraepithelial lymphocytes increased, as did Smad2 expression. Blocking transforming growth factor beta reversed CDDO-induced protection and prevented the up-regulation of Smad2 in the small intestine.
CONCLUSIONS: CDDO acid is a novel anti-inflammatory molecule capable of preventing ileitis by activating the transforming growth factor beta signaling pathway in a pathogen-driven ileitis model. This could represent a new treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236178     DOI: 10.1053/j.gastro.2004.03.053

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.

Authors:  Steffen Koschmieder; Francesco D'Alò; Hanna Radomska; Christine Schöneich; Ji Suk Chang; Marina Konopleva; Susumu Kobayashi; Elena Levantini; Nanjoo Suh; Annalisa Di Ruscio; Maria Teresa Voso; Julie C Watt; Ramasamy Santhanam; Bülent Sargin; Hagop Kantarjian; Michael Andreeff; Michael B Sporn; Danilo Perrotti; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve; Daniel G Tenen
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

Review 2.  Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2.

Authors:  Qiang Ma; Xiaoqing He
Journal:  Pharmacol Rev       Date:  2012-09-10       Impact factor: 25.468

Review 3.  Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.

Authors:  Karen T Liby; Michael B Sporn
Journal:  Pharmacol Rev       Date:  2012-09-10       Impact factor: 25.468

4.  The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality.

Authors:  Kai Sun; Minghui Li; Marina Konopleva; Sergej Konoplev; L Clifton Stephens; Steven M Kornblau; Olga Frolova; Danice E C Wilkins; Weihong Ma; Lisbeth A Welniak; Michael Andreeff; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-26       Impact factor: 5.742

Review 5.  Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.

Authors:  Minghui Li; Kai Sun; Lisbeth A Welniak; William J Murphy
Journal:  Expert Opin Pharmacother       Date:  2008-09       Impact factor: 3.889

6.  Extracted Triterpenes from Antrodia cinnamomea Reduce the Inflammation to Promote the Wound Healing via the STZ Inducing Hyperglycemia-Diabetes Mice Model.

Authors:  Yu-Sheng Wu; Shiu-Nan Chen
Journal:  Front Pharmacol       Date:  2016-06-13       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.